Price
Financials
Standalone, Rs crore| Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 72 | 63 | 46 | 82 | 99 | 93 | 101 | 98 | 91 | 76 | 74 | 71 |
| Expenses | 60 | 59 | 40 | 78 | 94 | 85 | 94 | 92 | 82 | 74 | 76 | 71 |
| Operating Profit | 12 | 5 | 6 | 4 | 5 | 7 | 8 | 6 | 9 | 3 | -2 | 0 |
| OPM % | 17% | 7% | 13% | 4.3% | 5% | 8% | 8% | 6% | 10% | 3.4% | -3.2% | 0.2% |
| Other Income | 0 | 0 | 1 | 6 | 6 | 0 | 4 | 4 | 1 | 3 | 3 | -7 |
| Interest | 2 | 2 | 2 | 2 | 1 | 3 | 2 | 2 | 1 | 2 | 2 | 2 |
| Depreciation | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 2 | 2 |
| Profit before tax | 7 | 0 | 2 | 6 | 8 | 3 | 7 | 6 | 7 | 2 | -4 | -11 |
| Tax % | 0% | 3,780% | 25% | 31% | 32% | 46% | 28% | 10% | 30% | 35% | -1% | -1% |
| Net Profit | 7 | -2 | 2 | 4 | 5 | 2 | 5 | 6 | 5 | 1 | -4 | -11 |
| EPS in Rs | 4.10 | -1.01 | 0.90 | 2.09 | 2.81 | 0.91 | 2.83 | 3.07 | 2.64 | 0.61 | -2.17 | -6.16 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 91 | 122 | 137 | 148 | 127 | 128 | 135 | 127 | 192 | 200 | 168 | 144 |
| Expenses | 86 | 112 | 127 | 130 | 107 | 117 | 118 | 118 | 179 | 186 | 155 | 147 |
| Operating Profit | 5 | 10 | 10 | 17 | 20 | 11 | 17 | 9 | 13 | 14 | 12 | -2 |
| OPM % | 5% | 8% | 7% | 12% | 16% | 8% | 12% | 7% | 7% | 7% | 7% | -1.5% |
| Other Income | 0 | 1 | 3 | 2 | 1 | 6 | 0 | 7 | 6 | 8 | 4 | -5 |
| Interest | 1 | 4 | 3 | 7 | 5 | 4 | 4 | 4 | 4 | 4 | 3 | 4 |
| Depreciation | 1 | 3 | 3 | 5 | 5 | 5 | 5 | 5 | 4 | 4 | 5 | 5 |
| Profit before tax | 3 | 4 | 8 | 7 | 10 | 8 | 8 | 8 | 11 | 13 | 9 | -15 |
| Tax % | 24% | 10% | 27% | 30% | 26% | 18% | 25% | 29% | 36% | 20% | 31% | -1% |
| Net Profit | 2 | 4 | 6 | 5 | 8 | 6 | 6 | 5 | 7 | 11 | 6 | -15 |
| EPS in Rs | 7.62 | 15.03 | 18.83 | 2.81 | 4.21 | 3.46 | 3.09 | 2.99 | 3.72 | 5.89 | 3.25 | -8.32 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 8% | 15% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | 2% | 1% | -9% | -14% | ||
| Compounded Profit Growth | % | % | % | -157% | ||
| Stock Price CAGR | % | 10% | -22% | -37% | ||
| Return on Equity | 8% | 6% | 5% | -7% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3 | 3 | 3 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 |
| Reserves | 12 | 16 | 21 | 40 | 48 | 54 | 59 | 65 | 71 | 82 | 87 | 72 |
| Borrowings | 52 | 58 | 65 | 56 | 51 | 42 | 43 | 44 | 28 | 23 | 34 | 35 |
| Other Liabilities | 18 | 11 | 18 | 20 | 16 | 19 | 22 | 22 | 21 | 17 | 29 | 28 |
| Total Liabilities | 84 | 87 | 107 | 133 | 133 | 133 | 143 | 148 | 138 | 140 | 168 | 153 |
| Fixed Assets | 44 | 42 | 41 | 64 | 63 | 60 | 64 | 50 | 49 | 40 | 37 | 35 |
| CWIP | 0 | 1 | 21 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 4 |
| Other Assets | 40 | 44 | 44 | 70 | 70 | 72 | 79 | 98 | 89 | 98 | 127 | 113 |
| Total Assets | 84 | 87 | 107 | 133 | 133 | 133 | 143 | 148 | 138 | 140 | 168 | 153 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 0 | 3 | 13 | 2 | 14 | 16 | 11 | -7 | 26 | 15 | 29 | 11 |
| Cash from Investing Activity | 0 | -2 | -19 | -5 | -4 | -2 | -9 | 10 | -6 | -1 | -29 | -16 |
| Cash from Financing Activity | 0 | -1 | 6 | 5 | -11 | -14 | -3 | -3 | -20 | -10 | 10 | -3 |
| Net Cash Flow | 0 | 0 | -0 | 2 | -2 | 1 | -1 | 0 | 0 | 4 | 9 | -9 |
| Free Cash Flow | 0 | 1 | -6 | -3 | 10 | 14 | 2 | 3 | 23 | 14 | 7 | 3 |
| CFO/OP | 0% | 27% | 128% | 13% | 76% | 152% | 67% | -63% | 219% | 126% | 254% | -470% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 133 | 49 | 64 | 89 | 82 | 65 | 60 | 112 | 67 | 72 | 39 | 26 |
| Inventory Days | 15 | 58 | 37 | 44 | 79 | 94 | 126 | 106 | 65 | 55 | 117 | 134 |
| Days Payable | 44 | 14 | 13 | 15 | 16 | 28 | 25 | 18 | 16 | 10 | 29 | 19 |
| Cash Conversion Cycle | 105 | 93 | 88 | 117 | 145 | 131 | 161 | 200 | 116 | 117 | 127 | 141 |
| Working Capital Days | 43 | 24 | 1 | 47 | 66 | 70 | 66 | 110 | 96 | 116 | 120 | 130 |
| ROCE % | 6% | 12% | 13% | 14% | 14% | 10% | 10% | 9% | 12% | 14% | 14% | -3% |
| Mar 2020 | Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 62.30% | 62.33% | 62.33% | 62.33% | 62.33% | 62.33% | 63.28% | 63.28% | 63.28% | 64.02% | 64.02% | 64.02% |
| FIIs | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.05% | 0.05% | 0.05% | 0.05% | 0.05% | 0.00% | 0.00% |
| DIIs | 1.86% | 1.76% | 1.58% | 1.25% | 1.22% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 35.84% | 35.91% | 36.10% | 36.42% | 35.25% | 36.42% | 34.18% | 34.18% | 35.38% | 34.64% | 34.96% | 34.96% |
| Others | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1.01% |
| No. of Shareholders | 397 | 408 | 373 | 575 | 616 | 616 | 597 | 593 | 733 | 749 | 737 | 639 |
Fundamentals
Market Cap₹ 59.3 Cr.
Current Price₹ 32.5
Book Value₹ 49.5
ROCE-2.71 %
ROE-7.28 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)-14%
Compounded Profit Growth (TTM)-157%
Standalone figures.
Valuation
Market capRs 57 Cr
Enterprise valueRs 87 Cr
Price to book0.63x
Price to sales0.40x
EV / sales0.60x
Price to cash flow5.41x
Earnings yield-26.55%
P/E, 3-year average13.72x
P/B, 3-year average0.91x
P/E, 5-year average12.56x
P/B, 5-year average0.87x
Profitability
Operating margin (excl. other income)-1.52%
Operating margin (incl. other income)-4.91%
EBITDA margin-4.91%
Pre-tax margin-10.59%
Net profit margin-10.51%
ROE-15.51%
ROCE-8.80%
ROA-9.45%
ROE, 3-year average0.52%
ROCE, 3-year average4.94%
ROA, 3-year average0.71%
ROE, 5-year average3.25%
ROCE, 5-year average7.19%
ROA, 5-year average2.12%
ROIC (approx.)-9.63%
Tax rate0.78%
Other income / net worth-5.44%
Growth
Sales growth (latest year)-13.89%
Profit growth (latest year)-355.99%
Sales CAGR, 3 years-9.05%
Sales CAGR, 5 years1.34%
Per share
EPS (TTM)Rs -8.32
EPS (latest year)Rs -8.32
EPS, 3-year averageRs 0.27
EPS, 5-year averageRs 1.51
Book value per shareRs 49.52
Sales per shareRs 79.22
Cash flow per shareRs 5.79
Free cash flow per shareRs 1.65
Dividend per share, 3-year averageRs 0.50
Dividend per share, 5-year averageRs 0.50
Dividends
Dividend payout, 3-year average11.91%
Dividend payout, 5-year average11.91%
Efficiency
Asset turnover0.94x
Fixed asset turnover4.08x
Inventory turnover2.99x
Inventory days122 days
Debtor days26 days
Debtors turnover14.23x
Creditor days19 days
Cash conversion cycle141 days
Working capital days130 days
Leverage
Total debtRs 35 Cr
Cash and bankRs 5 Cr
Net debtRs 29 Cr
Debt to equity0.39x
Interest coverage-3.17x
Owners' fund to total sources58.93%
Debt to assets22.69%
Cash flow
Cash from Operating Activity (latest year)Rs 11 Cr
Cash from Investing Activity (latest year)Rs -16 Cr
Cash from Financing Activity (latest year)Rs -3 Cr
Net Cash Flow (latest year)Rs -9 Cr
Free cash flow (latest year)Rs 3 Cr
FCFE (approx.: FCF + change in debt)Rs 4 Cr
Cash from ops / profit, 5 years5.29x
Sales to cash flow13.68x
Statement figures
Net sales (TTM)Rs 144 Cr
Net sales (latest year)Rs 144 Cr
Operating profit excl. other income (latest year)Rs -2 Cr
Other income (TTM)Rs -5 Cr
EBITDA (TTM)Rs -7 Cr
PBDT (TTM)Rs -11 Cr
Profit before tax (TTM)Rs -15 Cr
Tax (latest year)Rs -0 Cr
Net profit (TTM)Rs -15 Cr
Net profit (latest year)Rs -15 Cr
Depreciation (TTM)Rs 5 Cr
Interest (TTM)Rs 4 Cr
Cost of goods sold (latest year)Rs 109 Cr
Total expenditure (latest year)Rs 147 Cr
Total income (latest year)Rs 140 Cr
Share capitalRs 18 Cr
ReservesRs 72 Cr
Shareholders' fundsRs 90 Cr
Total assetsRs 153 Cr
Net blockRs 35 Cr
Capital work in progressRs 1 Cr
InvestmentsRs 4 Cr
ReceivablesRs 10 Cr
InventoryRs 36 Cr
Other liabilitiesRs 28 Cr
Shares outstanding (crore)1.82
Ownership
Promoter holding64.02% (+0.74 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/B 0.63 is at the 29th percentile (median 0.78).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | MHHL | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | +2.5% | -2.8% | +5.2 pts |
| 1 month | -11.2% | -6.8% | -4.4 pts |
| 3 months | -19.6% | -7.6% | -12.0 pts |
| 6 months | -15.7% | +0.4% | -16.1 pts |
| 1 year | -51.0% | -9.9% | -41.1 pts |
| 2 years | -45.0% | -13.6% | -31.4 pts |
| 3 years | -55.6% | +14.2% | -69.7 pts |
| 5 years | +48.9% | +27.9% | +21.0 pts |
Red flags
F-score 3 of 8No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Mar 2026Sales ₹71 Cr -27.6% vs Mar 2024.
Net loss ₹11 Cr.
Against our estimate for Mar 2026: sales +17.6%, profit -635.1% big miss.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Poly Medicure Ltd | 16,671 | 52.1 | 12.5 % |
| Molbio Diagnostics Ltd | 14,470 | 66.6 | 18.0 % |
| Fischer Medical Ventures Ltd | 2,355 | 96.2 | 11.4 % |
| Tarsons Products Ltd | 1,754 | 148 | 4.59 % |
| Q-Line Biotech Ltd | 1,569 | 27.8 | 22.5 % |
| Laxmi Dental Ltd | 1,058 | 30.4 | 15.0 % |
| Hemant Surgical Industries Ltd | 869 | 51.3 | 18.9 % |
| Vasa Denticity Ltd | 754 | 62.3 | 7.54 % |
| OSEL Devices Ltd | 691 | 23.6 | 24.4 % |
| Prevest Denpro Ltd | 462 | 20.5 | 24.9 % |
| QMS Medical Allied Services Ltd | 419 | 39.0 | 12.9 % |
| Nureca Ltd | 349 | 80.4 | 3.30 % |
| Aprameya Engineering Ltd | 200 | 39.7 | 12.6 % |
| Avience Biomedicals Ltd | 198 | 22.7 | 27.0 % |
| Earkart Limited | 179 | 36.3 | 17.5 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
| Order date | Forum | Case |
|---|---|---|
| 2021-07-13 | NCLT | Mohini Health & Hygiene Ltd. Vs Vinayak Manutrade Pvt. Ltd. |
| 2020-03-04 | NCLT | Mohini Health & Hygiene Ltd. Vs Vinayak Manutrade Pvt. Ltd. |
Orders from NCLT, NCLAT and CESTAT naming the company. Click a row for the order.
EPS in the scrip is zero (4 trailing quarters)Less than 100 unique PAN traded in previous 30 daysMandatory Market making period in SME scrip is overSME scrip is not regularly traded
Quick answers
What is the market cap of Mohini Health & Hygiene Ltd?
Mohini Health & Hygiene Ltd (MHHL) has a market capitalisation of Rs 59.3 Cr. at the 2026-09-30 close.
What were Mohini Health & Hygiene Ltd's latest quarterly results?
In the Mar 2026 quarter, Mohini Health & Hygiene Ltd sales was Rs 71 Cr (-27.6% vs Mar 2024) with a net loss of Rs 11 Cr.
What is the 52-week high and low of Mohini Health & Hygiene Ltd?
The 52-week high is Rs 53.95 and the 52-week low is Rs 29.20.